Nakagami, Hironori
Ishihama, Tetsuya
Daikyoji, Yuichi
Sasakura, Chieka
Yamada, Ei
Morishita, Ryuichi
Article History
Received: 29 August 2021
Revised: 2 September 2021
Accepted: 6 September 2021
First Online: 17 October 2021
Compliance with ethical standards
:
: The Department of Health Development and Medicine is an endowed department supported by AnGes, Daicel, and FunPep and collaborated with these companies. The Department of Clinical Gene Therapy is financially supported by Novartis, AnGes, Shionogi, Boehringer, Fancl, Rohto, and FunPep. R.M. is a stockholder of AnGes and Funpep, and honoraria from Anges. H.N. is a scientific advisor of Funpep. T.I., Y.D., C.D., T.K., Y.S., K.S., A.M., and E. Y are employees and stockholders of AnGes.
: This study was approved by the Bellberry Human Research Ethics Committee (HREC), which was founded by the National Health and Medical Research Council and operates in accordance with its National Statement on Ethical Conduct in Human Research. The protocol has been summarized, and detailed information has been found in trials registered on ANZCTR (ACTRN12617001192370).